Revolution Medicines 

$151.07
63
+$3.86+2.62% Today

Statistics

Day High
151.49
Day Low
145.29
52W High
153.37
52W Low
34.7
Volume
671,924,111
Avg. Volume
-
Mkt Cap
29.94B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
-2.29
-1.82
-1.36
-0.89
Expected EPS
-1.84
Actual EPS
-2.29

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-2.26BNet Income

Analyst Ratings

157.13Average Price Target
The highest estimate is 215.00.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RVMD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap178B
Amgen is a biotech giant that competes in the oncology space, developing treatments that could directly compete with Revolution Medicines' cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including cancer, which puts it in direct competition with Revolution Medicines.
Merck
MRK
Mkt Cap277.02B
Merck is a global healthcare company that produces cancer drugs and therapies, competing with Revolution Medicines in the oncology market.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including oncology, competing with Revolution Medicines' cancer treatment portfolio.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a global pharmaceutical corporation with a broad range of oncology products, competing with Revolution Medicines in the cancer treatment space.
Novartis
NVS
Mkt Cap279.67B
Novartis is a global healthcare company that has a strong focus on pharmaceuticals and biotechnology, including oncology, making it a competitor to Revolution Medicines.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie is a pharmaceutical company that engages in the discovery, development, manufacture, and sale of a broad line of healthcare products including oncology, competing with Revolution Medicines.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG is a healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its extensive work in oncology competes with Revolution Medicines.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with Revolution Medicines.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including cancer, competing with Revolution Medicines.

About

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Show more...
CEO
Dr. Mark A. Goldsmith M.D., Ph.D.
Employees
616
Country
United States
ISIN
US76155X1000

Listings

0 Comments

Share your thoughts

FAQ

What is Revolution Medicines stock price today?
The current price of RVMD is $151.07 USD — it has increased by +2.62% in the past 24 hours. Watch Revolution Medicines stock price performance more closely on the chart.
What is Revolution Medicines stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Revolution Medicines stocks are traded under the ticker RVMD.
Is Revolution Medicines stock price growing?
RVMD stock has risen by +7.48% compared to the previous week, the month change is a +58.42% rise, over the last year Revolution Medicines has showed a +303.5% increase.
What is Revolution Medicines market cap?
Today Revolution Medicines has the market capitalization of 29.94B
What were Revolution Medicines earnings last quarter?
RVMD earnings for the last quarter are -2.29 USD per share, whereas the estimation was -1.84 USD resulting in a -24.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Revolution Medicines revenue for the last year?
Revolution Medicines revenue for the last year amounts to 0 USD.
What is Revolution Medicines net income for the last year?
RVMD net income for the last year is -2.26B USD.
How many employees does Revolution Medicines have?
As of May 06, 2026, the company has 616 employees.
In which sector is Revolution Medicines located?
Revolution Medicines operates in the Health & Wellness sector.
When did Revolution Medicines complete a stock split?
Revolution Medicines has not had any recent stock splits.
Where is Revolution Medicines headquartered?
Revolution Medicines is headquartered in Redwood City, United States.